Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD

Background: The effects of pharmacologic treatment on physical activity (PA) are still unclear, especially in treatment naive patients with COPD. We investigated the effects of a newly introduced bronchodilator on pulmonary function, dyspnea, QOL and PA in COPD patients. Methods: In this prospective, randomized interventional study, 78 treatment naive COPD subjects without any other diseases that might reduce PA were recruited. The subjects were randomized to receive either tiotropium (Tio) or tiotropium/olodaterol (Tio/Olo) combination treatment for 12-weeks. PA levels were measured with a triaxle accelerometer for 2 weeks were administered before and after 12-weeks treatment. Results: Adjusted mean forced expiratory volume in 1 second (FEVl.0) after administration of the bronchodilator for 12-weeks was 224±156 mL with Tio/Olo vs. 105±203 mL with Tio (p<0.01). The duration of PA at ≥ 2.0 METs were improved in both groups after 12-weeks treatment. The change in the duration of PA at ≥ 2.0 METs was increased in both the Tio/Olo (17.7±53.4 min) and the Tio (5.7±50.6 min) group (p=0.37), which tended to greater increase in the Tio/Olo. The change in the duration of PA 1.0-1.5 METs, which represent the sedentary position, was decreased in both the Tio/Olo (-55.0±116.4 min) and the Tio (-36.2±123.1 min) group (p=0.54), which tended to decrease in the Tio/Olo. Conclusion: Tio/Olo significantly improved FEV1.0 compared with Tio in patients with treatment naive COPD. Both Tio/Olo and Tio decreased the amount of time spent in the sedentary position, and increased the duration of ≥ 2.0 METs PA.